The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2019 | Myelofibrosis: LSD1 inhibitor IMG-7289
Kristen Pettit
• 15 Jun 2019
Kristen Pettit, MD, University of Michigan, Ann Arbor, MI, tells us about the use of the LSD1 inhibitor IMG-7289 in the treatment of myelofibrosis. This interview took place at the 24th Congress of the European Hematology Association (EHA) 2019, held in Amsterdam, Netherlands.
